Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > FDA completion Phase 2 , Qixleef, anticipated April 2023

<< Previous

Bullboard Posts

Next >>

Comment by SamV21on Feb 06, 2022 11:53pm

56 Views

Post# 34403400

RE:RE:FDA completion Phase 2 , Qixleef, anticipated April 2023

https://clinicaltrials.gov/ct2/history/NCT04042545?V_7=View#StudyPageTop

4 week trial then 1 year open trial , meaning 1 year of the patients knowing if they get the real drug or the placebo. So anticipated or maybe April 2023 ,(Guy said he was going to be selling Reduvo 4th quarter 2021) look at the results dates on the FDA site don't listen to these know nothing exaggerating pumpers .Wait for the results, anything other than that is just false hype and pumping.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property